NCT06305741 A Study of an Anxiety Intervention for Latino/Latina/Hispanic Older Adults With Cancer and Their Caregivers
| NCT ID | NCT06305741 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Cancer Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-05 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-03-05 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to find out if an anxiety treatment program is practical and effective for Latino older adults with cancer (OACs) and their caregivers.
Eligibility Criteria
Inclusion Criteria: Older Adults with Cancer (OAC) * As per medical record or self-report, is currently age 65 years or older * As per medical record or self-report, currently receiving active cancer treatment OR is within eighteen months of completing active treatment which includes surgery, chemotherapy, radiation, and immunotherapy. * As per self-report, identifies as Latino and/or Hispanic Ethnicity * Per self-report, has a primary informal caregiver (as defined by an unpaid individual who provides the patient with emotional, physical, and/or practical support) age 40 or older who is willing and able to participate in the study ; if a patient does not have a primary informal caregiver or if the caregiver does not or cannot participate, but meets all other inclusion criteria they will be allowed to enroll in the study * Scores ≥6 on the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS) * Per self-report, fluent in English and/or Spanish\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify language fluency necessary for participation in the study: 1. How well do you speak English and/or Spanish? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused) 2. What is your preferred language for healthcare? (must respond English and/or Spanish) Caregiver * Per OAC report, is primary informal caregiver (as defined by an unpaid individual who provides the patient with emotional, physical, and/or practical support) for the eligible OAC patient * As per self-report, is age 40 years or older * Per self-report, fluent in English and/or Spanish\*\* \*\* Language verification: Prior to enrollment, patients will be asked the following two questions by a Clinical Research Coordinator (CRC) to verify language fluency necessary for participation in the study: 1. How well do you speak English and/or Spanish? (must respond "very well" or "well" when given the choices of Very well, Well, Not well, Not at all, Don't know, or Refused) 2. What is your preferred language for healthcare? (must respond English and/or Spanish) Exclusion Criteria: OAC * As per medical record or self-report, currently receiving psychotherapy * As per medical record or self-report, taking psychotropic medications for \< 8 weeks prior to MAC Session 1 and/or anticipates changing their medication during the study * As per medical record or self-report, currently being treated for schizophrenia, substance use or dependence, and/or bi-polar disorder * Severely cognitively impaired as demonstrated by Blessed Orientation Memory Concentration score ≥ 11 * Per research staff judgment and/or self-report, too ill or weak to complete study procedures * Per medical record or self-report, receiving hospice care at the time of enrollment Caregiver * As per self-report, currently receiving psychotherapy * As per self-report, taking psychotropic medications for \< 8 weeks prior to MAC Session 1 and/or anticipates changing their medication during the study * As per self-report, currently being treated for schizophrenia, substance use or dependence, and/or bi-polar disorder * Severely cognitively impaired as demonstrated by Blessed Orientation Memory Concentration score ≥ 11 * Per research staff judgment and/or self-report, too ill or weak to complete study procedures
Contact & Investigator
Kelly McConnell, PhD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT06305741 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Cancer Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06305741 currently recruiting?
Yes, NCT06305741 is actively recruiting participants. Contact the research team at mcconnek@mskcc.org for enrollment information.
Where is the NCT06305741 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT06305741 clinical trial?
NCT06305741 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Kelly McConnell, PhD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.